液相色谱串联质谱法同时测定人血浆中氯雷他定和地氯雷他定浓度的方法
By combining liquid chromatography-tandem mass spectrometry with methyl tert-butyl ether extraction and a specific gradient elution procedure, the problem of determining the concentration of loratadine and desloratadine in human plasma has been solved, achieving simultaneous detection with high accuracy and sensitivity, and meeting the needs of precise clinical drug evaluation.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- SHANGHAI WEIPU PHARM TECH CO LTD
- Filing Date
- 2026-05-08
- Publication Date
- 2026-07-17
AI Technical Summary
Current technologies cannot simultaneously and accurately measure the concentrations of loratadine and desloratadine in human plasma, and are deficient in terms of selectivity, durability, and accuracy, failing to fully reflect the metabolic process and mechanism of action of the drugs in the body.
The separation and detection of loratadine and desloratadine were achieved by using liquid chromatography-tandem mass spectrometry combined with methyl tert-butyl ether extraction and a specific gradient elution program, using a C18 chemically bonded column and dedicated mass spectrometry parameters, while reducing plasma matrix interference.
Simultaneous detection of loratadine and desloratadine was achieved, reducing matrix effects and improving detection accuracy and sensitivity, thus meeting the needs of precise clinical drug assessment.
Smart Images
Figure CN122409900A_ABST
Abstract
Citation Information
Patent Citations
Method for determining concentration of loratadine in blood plasma through liquid chromatography-tandem mass spectrometry
CN112505162A
Method for detecting rupatadine, desloratadine and 3-hydroxy desloratadine in human plasma by HPLC-MS / MS (High Performance Liquid Chromatography-Mass Spectrometry / Mass Spectrometry)
CN117630199A